Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography
Thymidylate synthase (EC 2.1.1.45) is a key enzyme for the de novo synthesis of DNA and as such a target for anticancer drug development. There is a need to develop noninvasive methods for assessing thymidylate synthase inhibition in tumors. The aim of this study was to assess the potential of 3...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 66; no. 17; pp. 8558 - 8564 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
01.09.2006
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Thymidylate synthase (EC 2.1.1.45) is a key enzyme for the de novo synthesis of DNA and as such a target for anticancer drug development. There is a need to develop noninvasive methods for assessing thymidylate synthase inhibition in tumors. The aim of this study was to assess the potential of 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) positron emission tomography (PET) for early measurement of thymidylate synthase inhibition and to elucidate the cellular mechanisms involved. Radiation-induced fibrosarcoma-1 tumor-bearing mice were injected with a single i.p. dose of the thymidylate synthase inhibitor 5-fluorouracil (5-FU; 165 mg/kg) and imaged by [(18)F]FLT-PET at 1 to 2 hours after treatment. Deoxyuridine, thymidine kinase 1 (cytoplasmic thymidine kinase; EC2.7.1.21), and ATP levels in excised tumors were measured. Cellular assays for membrane transport were also done. There was a 1.8-fold increase in the 60-minute [(18)F]FLT tumor/heart radioactivity ratio in drug-treated mice compared with vehicle controls (P = 0.0016). Plasma and tumor deoxyuridine levels increased significantly but thymidine kinase and ATP levels were unchanged. Whole-cell assays implicated a (low level) functional role for the type-1 equilibrative nucleoside transporter (ENT). There was an increase in type-1 ENT-binding sites per cell from 49,110 in untreated cells to 73,142 (P = 0.03) in cells treated with 10 microg/mL 5-FU for 2 hours, without a change in transporter affinity (P = 0.41). We conclude that [(18)F]FLT-PET can be used to measure thymidylate synthase inhibition as early as 1 to 2 hours after treatment with 5-FU by a mechanism involving redistribution of nucleoside transporters to the plasma membrane. |
---|---|
AbstractList | Thymidylate synthase (EC 2.1.1.45) is a key enzyme for the de novo synthesis of DNA and as such a target for anticancer drug development. There is a need to develop noninvasive methods for assessing thymidylate synthase inhibition in tumors. The aim of this study was to assess the potential of 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) positron emission tomography (PET) for early measurement of thymidylate synthase inhibition and to elucidate the cellular mechanisms involved. Radiation-induced fibrosarcoma-1 tumor-bearing mice were injected with a single i.p. dose of the thymidylate synthase inhibitor 5-fluorouracil (5-FU; 165 mg/kg) and imaged by [(18)F]FLT-PET at 1 to 2 hours after treatment. Deoxyuridine, thymidine kinase 1 (cytoplasmic thymidine kinase; EC2.7.1.21), and ATP levels in excised tumors were measured. Cellular assays for membrane transport were also done. There was a 1.8-fold increase in the 60-minute [(18)F]FLT tumor/heart radioactivity ratio in drug-treated mice compared with vehicle controls (P = 0.0016). Plasma and tumor deoxyuridine levels increased significantly but thymidine kinase and ATP levels were unchanged. Whole-cell assays implicated a (low level) functional role for the type-1 equilibrative nucleoside transporter (ENT). There was an increase in type-1 ENT-binding sites per cell from 49,110 in untreated cells to 73,142 (P = 0.03) in cells treated with 10 microg/mL 5-FU for 2 hours, without a change in transporter affinity (P = 0.41). We conclude that [(18)F]FLT-PET can be used to measure thymidylate synthase inhibition as early as 1 to 2 hours after treatment with 5-FU by a mechanism involving redistribution of nucleoside transporters to the plasma membrane. Thymidylate synthase (EC 2.1.1.45) is a key enzyme for the de novo synthesis of DNA and as such a target for anticancer drug development. There is a need to develop noninvasive methods for assessing thymidylate synthase inhibition in tumors. The aim of this study was to assess the potential of 3'-deoxy-3'-[ super(18)F]fluorothymidine ([ super(18)F]FLT) positron emission tomography (PET) for early measurement of thymidylate synthase inhibition and to elucidate the cellular mechanisms involved. Radiation-induced fibrosarcoma-1 tumor-bearing mice were injected with a single i.p. dose of the thymidylate synthase inhibitor 5-fluorouracil (5-FU; 165 mg/kg) and imaged by [ super(18)F]FLT-PET at 1 to 2 hours after treatment. Deoxyuridine, thymidine kinase 1 (cytoplasmic thymidine kinase; EC2.7.1.21), and ATP levels in excised tumors were measured. Cellular assays for membrane transport were also done. There was a 1.8-fold increase in the 60-minute [ super(18)F]FLT tumor/heart radioactivity ratio in drug-treated mice compared with vehicle controls (P = 0.0016). Plasma and tumor deoxyuridine levels increased significantly but thymidine kinase and ATP levels were unchanged. Whole-cell assays implicated a (low level) functional role for the type-1 equilibrative nucleoside transporter (ENT). There was an increase in type-1 ENT-binding sites per cell from 49,110 in untreated cells to 73,142 (P = 0.03) in cells treated with 10 mu g/mL 5-FU for 2 hours, without a change in transporter affinity (P = 0.41). We conclude that [ super(18)F]FLT-PET can be used to measure thymidylate synthase inhibition as early as 1 to 2 hours after treatment with 5-FU by a mechanism involving redistribution of nucleoside transporters to the plasma membrane. (Cancer Res 2006; 66(17): 8558-64) Abstract Thymidylate synthase (EC 2.1.1.45) is a key enzyme for the de novo synthesis of DNA and as such a target for anticancer drug development. There is a need to develop noninvasive methods for assessing thymidylate synthase inhibition in tumors. The aim of this study was to assess the potential of 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT) positron emission tomography (PET) for early measurement of thymidylate synthase inhibition and to elucidate the cellular mechanisms involved. Radiation-induced fibrosarcoma-1 tumor-bearing mice were injected with a single i.p. dose of the thymidylate synthase inhibitor 5-fluorouracil (5-FU; 165 mg/kg) and imaged by [18F]FLT-PET at 1 to 2 hours after treatment. Deoxyuridine, thymidine kinase 1 (cytoplasmic thymidine kinase; EC2.7.1.21), and ATP levels in excised tumors were measured. Cellular assays for membrane transport were also done. There was a 1.8-fold increase in the 60-minute [18F]FLT tumor/heart radioactivity ratio in drug-treated mice compared with vehicle controls (P = 0.0016). Plasma and tumor deoxyuridine levels increased significantly but thymidine kinase and ATP levels were unchanged. Whole-cell assays implicated a (low level) functional role for the type-1 equilibrative nucleoside transporter (ENT). There was an increase in type-1 ENT-binding sites per cell from 49,110 in untreated cells to 73,142 (P = 0.03) in cells treated with 10 μg/mL 5-FU for 2 hours, without a change in transporter affinity (P = 0.41). We conclude that [18F]FLT-PET can be used to measure thymidylate synthase inhibition as early as 1 to 2 hours after treatment with 5-FU by a mechanism involving redistribution of nucleoside transporters to the plasma membrane. (Cancer Res 2006; 66(17): 8558-64) |
Author | LEYTON, Julius PILLAI, Radhakrishna G BARTHEL, Henryk PERUMAL, Meg FORSTER, Martin JACKMAN, Ann L LATIGO, John R MITCHELL, Fraser ABOAGYE, Eric O |
Author_xml | – sequence: 1 givenname: Meg surname: PERUMAL fullname: PERUMAL, Meg organization: Molecular Therapy Group, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom – sequence: 2 givenname: Radhakrishna G surname: PILLAI fullname: PILLAI, Radhakrishna G organization: Molecular Therapy Group, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom – sequence: 3 givenname: Henryk surname: BARTHEL fullname: BARTHEL, Henryk organization: Molecular Therapy Group, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom – sequence: 4 givenname: Julius surname: LEYTON fullname: LEYTON, Julius organization: Molecular Therapy Group, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom – sequence: 5 givenname: John R surname: LATIGO fullname: LATIGO, John R organization: Molecular Therapy Group, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom – sequence: 6 givenname: Martin surname: FORSTER fullname: FORSTER, Martin organization: Section of Medicine, Institute of Cancer Research, Surrey, United Kingdom – sequence: 7 givenname: Fraser surname: MITCHELL fullname: MITCHELL, Fraser organization: Section of Medicine, Institute of Cancer Research, Surrey, United Kingdom – sequence: 8 givenname: Ann L surname: JACKMAN fullname: JACKMAN, Ann L organization: Section of Medicine, Institute of Cancer Research, Surrey, United Kingdom – sequence: 9 givenname: Eric O surname: ABOAGYE fullname: ABOAGYE, Eric O organization: Molecular Therapy Group, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18107246$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16951168$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkcGO1SAUhokZ49wZfQQNG911hBYoLCc36phMNDG6JpQebjFtqUAn6fv4oNKZG2cFHL7Dz3_-K3QxhxkQekvJDaVcfiSEyIqztr453n6riKiIVPIFOlDeyKpljF-gw3_mEl2l9LscOSX8FbqkQnFKhTygvz-g9ylH363ZhxkHh-fVjhCS7wHnaOa0hJghJpwDzgNgC-OIJ5i6cgd4ieGhkAkbPIcHGLFZSsnYAbsQsZ_Myc-n0rdNvt9GkwGnbc6DSYD9PPjOP6p2G16KYo5lD5NPaS_mMIVTNMuwvUYvnRkTvDmv1-jX508_j3fV_fcvX4-395XllOeq5lIppowSRPS2pVLUNTTWKEKappOulVYITpltTOeMdK7uG8tay5UE6nrSXKMPT-8WC39WSFmXv-x-i9OwJk0V44o2rID8CbQxpBTB6SUWr3HTlOg9Hr2PXu-j1yUeTYTe4yl9784CazdB_9x1zqMA78-ASdaMrszY-vTMSUramonmH5ybn3M |
CODEN | CNREA8 |
CitedBy_id | crossref_primary_10_1016_j_jtocrr_2022_100382 crossref_primary_10_2967_jnumed_107_048231 crossref_primary_10_3390_diagnostics10030125 crossref_primary_10_1158_0008_5472_CAN_17_1406 crossref_primary_10_2967_jnumed_110_086967 crossref_primary_10_1016_j_bcp_2010_08_004 crossref_primary_10_1007_s00259_008_0960_5 crossref_primary_10_1007_s11307_012_0590_y crossref_primary_10_1158_1078_0432_CCR_07_4294 crossref_primary_10_1371_journal_pone_0063705 crossref_primary_10_1016_j_ijrobp_2008_12_039 crossref_primary_10_1016_j_nucmedbio_2021_03_001 crossref_primary_10_1016_j_nucmedbio_2012_07_007 crossref_primary_10_1039_c0ib00066c crossref_primary_10_3390_cancers15143718 crossref_primary_10_1007_s12149_009_0332_7 crossref_primary_10_1016_j_nucmedbio_2009_06_001 crossref_primary_10_1158_0008_5472_CAN_16_1479 crossref_primary_10_1158_1078_0432_CCR_09_1213 crossref_primary_10_1007_s10555_008_9148_5 crossref_primary_10_1259_bjr_77317821 crossref_primary_10_1016_j_nucmedbio_2016_05_009 crossref_primary_10_1371_journal_pone_0202384 crossref_primary_10_1016_j_jorganchem_2018_05_009 crossref_primary_10_1016_j_ejca_2011_11_035 crossref_primary_10_1002_hed_20770 crossref_primary_10_1053_j_semnuclmed_2007_11_006 crossref_primary_10_1016_j_ymeth_2009_03_009 crossref_primary_10_1021_bc900380n crossref_primary_10_1038_nrd2290 crossref_primary_10_1007_s00259_007_0452_z crossref_primary_10_1002_cmmi_368 crossref_primary_10_18632_oncotarget_12085 crossref_primary_10_18632_oncotarget_19751 crossref_primary_10_1097_RLU_0b013e31820aa1a1 crossref_primary_10_1158_0008_5472_CAN_08_0135 crossref_primary_10_3892_or_2012_2172 crossref_primary_10_2967_jnumed_112_117010 crossref_primary_10_1016_j_nucmedbio_2014_12_005 crossref_primary_10_2967_jnumed_114_140913 crossref_primary_10_1002_aoc_4424 crossref_primary_10_1016_j_critrevonc_2015_12_014 crossref_primary_10_1088_2050_6120_ac89cd crossref_primary_10_1124_mol_108_048900 crossref_primary_10_1002_cam4_1113 crossref_primary_10_1007_s40336_013_0047_6 crossref_primary_10_1186_s13550_017_0302_3 crossref_primary_10_2967_jnumed_115_157958 crossref_primary_10_2967_jnumed_108_057281 crossref_primary_10_1016_j_nucmedbio_2012_03_009 crossref_primary_10_1007_s00280_015_2718_7 crossref_primary_10_1016_j_nucmedbio_2011_03_009 crossref_primary_10_1111_j_1476_5381_2010_01160_x crossref_primary_10_1158_1535_7163_MCT_12_0905 crossref_primary_10_2967_jnumed_112_112201 crossref_primary_10_1016_j_nucmedbio_2011_12_002 crossref_primary_10_18632_oncotarget_2123 crossref_primary_10_1039_C7MD00635G crossref_primary_10_1007_s11307_016_1021_2 crossref_primary_10_2967_jnumed_109_062208 crossref_primary_10_7314_APJCP_2014_15_10_4153 crossref_primary_10_1007_s00259_011_1802_4 crossref_primary_10_1158_1078_0432_CCR_11_0783 crossref_primary_10_2967_jnumed_110_076794 crossref_primary_10_1007_s11307_010_0351_8 crossref_primary_10_1007_s40336_014_0049_z crossref_primary_10_1038_bjc_2014_207 crossref_primary_10_1007_s12149_018_1229_0 crossref_primary_10_2967_jnumed_108_052027 crossref_primary_10_1053_j_semnuclmed_2008_12_001 crossref_primary_10_1186_s13550_016_0234_3 crossref_primary_10_2967_jnumed_108_055335 crossref_primary_10_2967_jnumed_119_240598 |
Cites_doi | 10.1016/S0959-8049(98)00226-3 10.1016/j.addr.2004.01.003 10.1073/pnas.80.21.6528 10.1016/j.clon.2003.10.009 10.1007/s002100000214 10.1038/sj.onc.1206952 10.1016/S0028-3908(97)00136-6 10.1016/S0378-4347(00)00260-7 10.1038/sj.bjc.6602216 10.1042/bj3270031 10.1007/s00259-005-0060-8 10.1093/jnci/95.9.675 10.1200/JCO.1988.6.10.1653 10.1042/bj3520363 10.1158/0008-5472.CAN-04-4008 10.1016/j.clinthera.2005.01.005 10.1200/JCO.1998.16.3.1131 10.1007/s002800050422 10.1158/0008-5472.CAN-05-2034 10.1074/jbc.M414337200 10.1074/jbc.M307938200 10.1007/s00259-002-0925-z 10.1200/JCO.2002.07.057 10.1056/NEJMra040958 10.1200/JCO.1994.12.10.2035 10.1002/jlcr.25804401306 10.1016/0065-2571(91)90008-A 10.1007/s00259-004-1611-0 10.1038/3337 10.1038/bjc.1998.1 10.1093/jnci/djj162 |
ContentType | Journal Article |
Copyright | 2006 INIST-CNRS |
Copyright_xml | – notice: 2006 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 8FD FR3 P64 |
DOI | 10.1158/0008-5472.CAN-06-0898 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | MEDLINE Engineering Research Database CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-7445 |
EndPage | 8564 |
ExternalDocumentID | 10_1158_0008_5472_CAN_06_0898 16951168 18107246 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Medical Research Council grantid: MC_U120081322 |
GroupedDBID | --- -ET .55 .GJ 08R 18M 29B 2WC 34G 39C 3O- 476 53G 5GY 5RE 5VS 6J9 8WZ A6W AAPBV AAUGY ABOCM ABPTK ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AETEA AFFNX AFHIN AFOSN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW C1A CS3 D0S DIK DU5 EBS EJD F5P FRP GX1 H13 IH2 IQODW J5H KQ8 L7B LSO MVM OHT OK1 P0W P2P PQQKQ RCR RHF RHI RNS SJN TR2 UDS VH1 W2D W8F WH7 WHG WOQ X7M XFK XJT YKV YZZ ZA5 ZCG ZGI CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 8FD FR3 P64 |
ID | FETCH-LOGICAL-c515t-2589949a9606dc718622e3ca90033b8f78c66514c3abfa8ff2d3c47c598e1fd03 |
ISSN | 0008-5472 |
IngestDate | Sat Aug 17 02:08:02 EDT 2024 Thu Sep 26 17:49:12 EDT 2024 Sat Sep 28 08:22:37 EDT 2024 Sun Oct 29 17:06:59 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 17 |
Keywords | Radionuclide study Methyltransferases Enzyme Transferases Plasma membrane Medical imagery Nucleoside Inhibition Thymidylate synthase Positron emission tomography Carrier protein Emission tomography |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c515t-2589949a9606dc718622e3ca90033b8f78c66514c3abfa8ff2d3c47c598e1fd03 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://cancerres.aacrjournals.org/content/canres/66/17/8558.full.pdf |
PMID | 16951168 |
PQID | 19459134 |
PQPubID | 23462 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_19459134 crossref_primary_10_1158_0008_5472_CAN_06_0898 pubmed_primary_16951168 pascalfrancis_primary_18107246 |
PublicationCentury | 2000 |
PublicationDate | 2006-09-01 |
PublicationDateYYYYMMDD | 2006-09-01 |
PublicationDate_xml | – month: 09 year: 2006 text: 2006-09-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Philadelphia, PA |
PublicationPlace_xml | – name: Philadelphia, PA – name: United States |
PublicationTitle | Cancer research (Chicago, Ill.) |
PublicationTitleAlternate | Cancer Res |
PublicationYear | 2006 |
Publisher | American Association for Cancer Research |
Publisher_xml | – name: American Association for Cancer Research |
References | 2022061622131586900_B14 2022061622131586900_B15 2022061622131586900_B12 2022061622131586900_B34 2022061622131586900_B13 2022061622131586900_B35 2022061622131586900_B18 2022061622131586900_B19 2022061622131586900_B16 2022061622131586900_B17 2022061622131586900_B10 2022061622131586900_B32 2022061622131586900_B11 2022061622131586900_B33 2022061622131586900_B30 2022061622131586900_B31 2022061622131586900_B25 2022061622131586900_B26 2022061622131586900_B23 2022061622131586900_B24 2022061622131586900_B29 2022061622131586900_B27 2022061622131586900_B28 2022061622131586900_B6 2022061622131586900_B5 2022061622131586900_B4 2022061622131586900_B3 2022061622131586900_B2 2022061622131586900_B1 2022061622131586900_B21 2022061622131586900_B9 2022061622131586900_B22 2022061622131586900_B8 2022061622131586900_B7 2022061622131586900_B20 |
References_xml | – ident: 2022061622131586900_B4 doi: 10.1016/S0959-8049(98)00226-3 – ident: 2022061622131586900_B6 doi: 10.1016/j.addr.2004.01.003 – ident: 2022061622131586900_B12 doi: 10.1073/pnas.80.21.6528 – ident: 2022061622131586900_B29 doi: 10.1016/j.clon.2003.10.009 – ident: 2022061622131586900_B27 doi: 10.1007/s002100000214 – ident: 2022061622131586900_B31 doi: 10.1038/sj.onc.1206952 – ident: 2022061622131586900_B26 doi: 10.1016/S0028-3908(97)00136-6 – ident: 2022061622131586900_B15 – ident: 2022061622131586900_B18 – ident: 2022061622131586900_B22 doi: 10.1016/S0378-4347(00)00260-7 – ident: 2022061622131586900_B23 doi: 10.1038/sj.bjc.6602216 – ident: 2022061622131586900_B25 doi: 10.1042/bj3270031 – ident: 2022061622131586900_B24 doi: 10.1007/s00259-005-0060-8 – ident: 2022061622131586900_B14 doi: 10.1093/jnci/95.9.675 – ident: 2022061622131586900_B3 doi: 10.1200/JCO.1988.6.10.1653 – ident: 2022061622131586900_B32 doi: 10.1042/bj3520363 – ident: 2022061622131586900_B20 doi: 10.1158/0008-5472.CAN-04-4008 – ident: 2022061622131586900_B5 doi: 10.1016/j.clinthera.2005.01.005 – ident: 2022061622131586900_B7 – ident: 2022061622131586900_B8 doi: 10.1200/JCO.1998.16.3.1131 – ident: 2022061622131586900_B9 doi: 10.1007/s002800050422 – ident: 2022061622131586900_B11 doi: 10.1158/0008-5472.CAN-05-2034 – ident: 2022061622131586900_B33 doi: 10.1074/jbc.M414337200 – ident: 2022061622131586900_B10 – ident: 2022061622131586900_B30 doi: 10.1074/jbc.M307938200 – ident: 2022061622131586900_B34 doi: 10.1007/s00259-002-0925-z – ident: 2022061622131586900_B28 doi: 10.1200/JCO.2002.07.057 – ident: 2022061622131586900_B1 doi: 10.1056/NEJMra040958 – ident: 2022061622131586900_B2 doi: 10.1200/JCO.1994.12.10.2035 – ident: 2022061622131586900_B17 doi: 10.1002/jlcr.25804401306 – ident: 2022061622131586900_B13 doi: 10.1016/0065-2571(91)90008-A – ident: 2022061622131586900_B21 doi: 10.1007/s00259-004-1611-0 – ident: 2022061622131586900_B16 doi: 10.1038/3337 – ident: 2022061622131586900_B19 doi: 10.1038/bjc.1998.1 – ident: 2022061622131586900_B35 doi: 10.1093/jnci/djj162 |
SSID | ssj0005105 |
Score | 2.2221854 |
Snippet | Thymidylate synthase (EC 2.1.1.45) is a key enzyme for the de novo synthesis of DNA and as such a target for anticancer drug development. There is a need to... Abstract Thymidylate synthase (EC 2.1.1.45) is a key enzyme for the de novo synthesis of DNA and as such a target for anticancer drug development. There is a... |
SourceID | proquest crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 8558 |
SubjectTerms | Animals Biological and medical sciences Cell Line, Tumor Cell Membrane - diagnostic imaging Cell Membrane - physiology Cell physiology Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes Fibrosarcoma - diagnostic imaging Fluorine Radioisotopes Fundamental and applied biological sciences. Psychology Mice Molecular and cellular biology Neoplasms, Radiation-Induced - diagnostic imaging Nucleoside Transport Proteins - metabolism Positron-Emission Tomography Thymidylate Synthase - antagonists & inhibitors |
Title | Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography |
URI | https://www.ncbi.nlm.nih.gov/pubmed/16951168 https://search.proquest.com/docview/19459134 |
Volume | 66 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa2ISEkNDGuHTD8wFuVkpsT57FMRR20BaZW2lvkxM5aqU2mNkUqv4cfyrEdJykb4vISRVYTK_m-2uecfOcchN7avp8ENAgsz-OR5XPGLSZ4YHHH5iINgsxxZHLyeBIMZ_7HK3J1cHjSUi1ty6SXfr8zr-R_UIUxwFVmyf4DsvVNYQDOAV84AsJw_CuML2VSbd2ySmsy4CeFbMEpmz9UZcvXG2NhyjB9dyVW4CLnMkNKZeFtuqybF9_Esi4wrrSHi5VuYARIrhZ8twSjVNY3KOew73UX-XyRKLWXtF-V8msN57J5nAy_wXyrdi3sphRCKtbdqsDQXH1B1lIQtVQtl71WYOLL4HI27o9UxFZc16MXo1H_QhGDcSlJWGzmOWs6hL0HA304GOkdNV_v6kQkMMSnnycmJfx2uCPak46Y71gt9qqXUj2B0SvurfnUIr5uENQTzTIf-rqQpdkHdPcXw_ewtapTosvLGwuB6MLrt3cfQrVcU0_YO-9PlKqMRrTZbo3E4JdduNZGgsllh64fHKJ7bhgRGVD49LWpgE8qWa6ZpMpKg6nf3Tnxnr318IZt4K-f6Z4tv3eqlHE1fYSOK68I9zXFT9CByB-j--NK9_EE_dhnOi4y3DAdt5mOywID07FkOjZMx4bpmGHFdGyYjgFUXDEdt5iODdNxw3Sc7LBhOjZMxw3Tn6LZh8H0fGhV_UWsFKz40nIJjSI_YtKJ5ykYaYHrCi9lMrjvJTQLKSxW4FCkHksyRrPM5V7qhymJqHAybnvP0FFe5OIFwnYiK9-RVCRh4meMU1moEsZcm6cu3K-DegaF-EaXkYmV-02olH_QWMIWA2yxlJkCbB10todVc1VFjw56Y8CL4YnlW4X3WWw3sRP5ROppOui5xrS5NgB_ygno6Z9u_hI9aP57r9BRud6K12B8l8mZYuNP5b3fkw |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Redistribution+of+nucleoside+transporters+to+the+cell+membrane+provides+a+novel+approach+for+imaging+thymidylate+synthase+inhibition+by+positron+emission+tomography&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=PERUMAL%2C+Meg&rft.au=PILLAI%2C+Radhakrishna+G&rft.au=BARTHEL%2C+Henryk&rft.au=LEYTON%2C+Julius&rft.date=2006-09-01&rft.pub=American+Association+for+Cancer+Research&rft.issn=0008-5472&rft.eissn=1538-7445&rft.volume=66&rft.issue=17&rft.spage=8558&rft.epage=8564&rft_id=info:doi/10.1158%2F0008-5472.CAN-06-0898&rft.externalDBID=n%2Fa&rft.externalDocID=18107246 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon |